<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2072-0351-5601</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-5601</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Постпрандиальная гипергликемия и сердечно-сосудистый риск</article-title><trans-title-group xml:lang="en"><trans-title>Total glucose control: the role of post-prandial glucose</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джеллингер</surname><given-names>Пауль С</given-names></name><name name-style="western" xml:lang="en"><surname>JELLINGER</surname><given-names>PAUL S</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Clinical Professor of Medicine University of Miami, Miami, Florida</institution></aff><aff xml:lang="en"><institution>Clinical Professor of Medicine University of Miami, Miami, Florida</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>15</day><month>06</month><year>2004</year></pub-date><volume>7</volume><issue>2</issue><issue-title>№2 (2004)</issue-title><fpage>4</fpage><lpage>8</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Джеллингер П.С., 2004</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="ru">Джеллингер П.С.</copyright-holder><copyright-holder xml:lang="en">JELLINGER P.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/5601">https://www.dia-endojournals.ru/jour/article/view/5601</self-uri><abstract><p>В работе обсуждается взаимосвязь между постпрандиальной гипергликемией и сердечно-сосудистым (СС) риском. Хотя профилактика микрососудистых заболеваний является важной целью терапии, осложнения сахарного диабета (СД) типа 2 в значительной степени затрагивают и сферу макрососудистого риска. СС заболевания и болезни периферических сосудов являются причиной значительно более высокой заболеваемости и смертности у пациентов с СД типа 2, чем классическая микрососудистая триада - нефропатия, нейропатия и ретинопатия, хотя опасность этих осложнений также очень высока. Заболевания периферических сосудов, возникающие вторично на фоне СД типа 2, являются одной из основных причин нетравматических ампутаций нижних конечностей, что составляет около 67 ООО ампутаций нижних конечностей в год (Американская диабетическая ассоциация, 2000; Центр по контролю и профилактике заболеваний, 1998). Сахарный диабет типа 2 связан с 2-4-кратным повышением риска патологии коронарных артерий и развития застойной сердечной недостаточности, а инфаркт миокарда (ИМ) является одной из наиболее распространенных причин летального исхода у пациентов с СД типа 2 (Американская диабетическая ассоциация, 2000; Американская кардиологическая ассо? циация, 1998; Центр по контролю и профилактике заболеваний, 1998; Национальный Институт кардиологии, пульмонологии и гематологии, 2000).</p></abstract><trans-abstract xml:lang="en"><p>The basis of strict glucose control and the achievement of a favorable HgbAlc must involve the control of both fasting and post-prandial glucose levels. Most of the day is spent in the post-prandial state. The most important predictor of post prandial glycemia is the pre-prandial glucose. Glucose control in the United States is far from optimal with a minority of patients achieving either the ADA goal of 7.0% or the ACE/AACE goal of 6.5%. There is evidence that post-meal glucose has a better correlation with A1C than fasting glucose levels especially when the A1C is less than 8%. A reduced early insulin release leads to high postprandial glucose. The evidence that lowering Hgb A1C results in lower microvascular risk is substantial. The DCC T demonstrated a clear association, of retinopathy with A1C . The study also demonstrated that for the same Al C, intensive glucose control using short-acting insulin pre-meals was associated with reduced complications compared to conventional treatment without short acting insulin. Further evidence from the Kumamoto Study and the UKPDS confirm reduced microvascular complications with lower A1C levels. Elevated mealtime glucose is an unappreciated concern at all levels of A1C including A1C levels at normal or near normal values. Elevated mealtime glucose is of special concern in the elderly. There is strong epidemiologic evidence linking post challenge hyperglycemia to macro-vascular risk. These include the Rancho Bernardo study the Honolulu Heart Study, the Paris Prospective Heart Study, The Diabetes Intervention Study, and the DECODE Study. There are many other studies going back to the 1980s that relate post-challenge or post-prandial blood glucose to cardiovascular disease risk and mortality. Possible effects of acute hyperglycemia responsible for increased microvascular and macrovascular risk include endothelial dysfunction, increased oxidative load, a pro-inflammatory state, protein glycosylation and altered coagulation. There is evidence that oral glucose loading adversely affects endothelial function. Oxidative load in the form of reactive oxygen species is increased following a glucose challenge. The pro-inflammatory state relates to quintiles of dietary glycemic load as it does to the 2- hour post challenge glucose category. There is evidence that in intimal media thickness increases more with the 2 hour glucose than A 1С. In summary, post mealtime glucose spikes are to be prevented because lowering A1C reduces microvascular complications, A1C reflects post mealtime glucose as well as fasting plasma group glucose, elevated post-meal glucose is a highly prevalent issue and elevated blood glucose 2 hours after a glucose load is associated with increased risk of death independent of fasting blood glucose. The Epic- Norfork study raises questions as to the level of A1C associated with risk. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>постпрандиальная гипергликемия</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>осложнения</kwd><kwd>сахарный диабет</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">American College of Endocrinology. //Endocr.Practice 2002; 8 (Suppl 1).</mixed-citation><mixed-citation xml:lang="en">American College of Endocrinology. //Endocr.Practice 2002; 8 (Suppl 1).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. // March 2000, online edition.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. // March 2000, online edition.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">American Heart Association.//American Heart Association, 1998.</mixed-citation><mixed-citation xml:lang="en">American Heart Association.//American Heart Association, 1998.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Avignon A., Radauceanu A., Monnier L. // Diabetes Care 1997; 20: 1822 - 1826</mixed-citation><mixed-citation xml:lang="en">Avignon A., Radauceanu A., Monnier L. // Diabetes Care 1997; 20: 1822 - 1826</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Barett-Connor E., Ferrara A. // Diabetes Care 1 998; 21:1236 - 1 239.</mixed-citation><mixed-citation xml:lang="en">Barett-Connor E., Ferrara A. // Diabetes Care 1 998; 21:1236 - 1 239.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Center for Disease Control and Prevention. National Diabetes Fact Sheet. 1 998, online edition.</mixed-citation><mixed-citation xml:lang="en">Center for Disease Control and Prevention. National Diabetes Fact Sheet. 1 998, online edition.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ceriello A. // Diabetic Med 1998; 15:188 - 193.</mixed-citation><mixed-citation xml:lang="en">Ceriello A. // Diabetic Med 1998; 15:188 - 193.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">DECODE Study Group on behalf of the European Diabetes Epidemiology Group. // Lancet 1999; 354: 617 - 621.</mixed-citation><mixed-citation xml:lang="en">DECODE Study Group on behalf of the European Diabetes Epidemiology Group. // Lancet 1999; 354: 617 - 621.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Diabetes Control and Complication Trial (DCCT) Research Group. // N Engl. J. Med 1993; 329: 997 - 986.</mixed-citation><mixed-citation xml:lang="en">Diabetes Control and Complication Trial (DCCT) Research Group. // N Engl. J. Med 1993; 329: 997 - 986.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Donahue RP., Abbott RD., Reed DM., Yano K. // Diabetes 1987; 36: 689-692.</mixed-citation><mixed-citation xml:lang="en">Donahue RP., Abbott RD., Reed DM., Yano K. // Diabetes 1987; 36: 689-692.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Eschwege Е., Richard JL., Thibult N. et al. // Horm Metab Res 1 985; 15 (Suppl): 41 - 46.</mixed-citation><mixed-citation xml:lang="en">Eschwege Е., Richard JL., Thibult N. et al. // Horm Metab Res 1 985; 15 (Suppl): 41 - 46.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Khaw KT., Wareham N., Luben R. et al. // Br Med J 2001; 322: 15 - 18.</mixed-citation><mixed-citation xml:lang="en">Khaw KT., Wareham N., Luben R. et al. // Br Med J 2001; 322: 15 - 18.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Malmberg K., Norhammar A., Wedel H., Ryden L. // Circulation 1 999; 99:2626-2632.</mixed-citation><mixed-citation xml:lang="en">Malmberg K., Norhammar A., Wedel H., Ryden L. // Circulation 1 999; 99:2626-2632.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">National Heart, Lung, and Blood Institute. // Bethesda, Md. 2000, online edition.</mixed-citation><mixed-citation xml:lang="en">National Heart, Lung, and Blood Institute. // Bethesda, Md. 2000, online edition.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ohkubo Y., Kishikawa H., Araki E. et al. // Diabetes Res Clin Pract 1995; 28: 103 -117.</mixed-citation><mixed-citation xml:lang="en">Ohkubo Y., Kishikawa H., Araki E. et al. // Diabetes Res Clin Pract 1995; 28: 103 -117.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Riddle MC. Evening insulin strategy. Diabetes Care 1990; 13: 676 - 686.</mixed-citation><mixed-citation xml:lang="en">Riddle MC. Evening insulin strategy. Diabetes Care 1990; 13: 676 - 686.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Temelkova-Kurktschiev TS., Koehler C., Henkel E. et al. // Diabetes Care 2000; 23: 1830- 1834.</mixed-citation><mixed-citation xml:lang="en">Temelkova-Kurktschiev TS., Koehler C., Henkel E. et al. // Diabetes Care 2000; 23: 1830- 1834.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">UK Prospective Study (UKPDS) Group. // Lancet 1998; 352: 837 - 853.</mixed-citation><mixed-citation xml:lang="en">UK Prospective Study (UKPDS) Group. // Lancet 1998; 352: 837 - 853.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Williams SB., Goldfine AB., Timimi FK. et al. // Circulation 1998; 97: 1695 - 1701.</mixed-citation><mixed-citation xml:lang="en">Williams SB., Goldfine AB., Timimi FK. et al. // Circulation 1998; 97: 1695 - 1701.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
